Cixi Chuangtuo New Material Technology Co., Ltd.

Cixi Chuangtuo New Materials Technology Co., Ltd. was established on July 6, 2017, with its registered office located at Room 2406, No. <24-2>, Langmu Building, Baisha Road, Cixi City, Zhejiang Province. The legal representative is Bian Deguang. The business scope includes general projects: technology services, technology development, technical consulting, technical exchanges, technology transfer, and technology promotion; sales of new organic active materials; sales of new film materials; research and development of biochemical products; sales of Class II medical devices; sales of labor protection supplies; sales of sanitary products and disposable medical supplies; sales of high-performance sealing materials; sales of eco-friendly materials; sales of graphene materials; sales of engineering plastics and synthetic resins; sales of high-performance fibers and composite materials; sales of chemical products (excluding licensed chemical products); sales of metal products; sales of thermal insulation and soundproofing materials; sales of industrial automatic control system equipment; sales of synthetic materials; wholesale of medical personnel protective equipment; wholesale of medical masks; sales of daily-use masks (non-medical); sales of textiles; recycling of renewable resources; trade brokerage; sales agency; domestic trade agency; sales of machinery and equipment; sales of coal and coal products; sales of petroleum products (excluding hazardous chemicals); wholesale of clothing and accessories; information technology consulting services; environmental protection consulting services; sales of plastic products (except for projects that require approval according to law, activities are conducted independently in accordance with the business license). Permitted projects: import and export of goods; import and export of technology; agency for imports and exports (activities can be carried out after being approved by relevant departments, specific business items are subject to the approval results).